Skip to content

National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. The 2014 Diagnosis and Staging Working Group Report

Madan Jagasia, Hildegard Greinix, Mukta Arora, Kirsten M. Williams, Daniel Wolff, Edward W. Cowen, Jeanne M. Palmer, Daniel Jordan Weisdorf, Nathaniel Simon Treister, Guang‐Shing Cheng, Holly Margaret Kerr, Pamela Stratton, Rafael F. Duarte, George B. McDonald, Yoshihiro Inamoto, Afonso Celso Vigorito, Sally Arai, Manuel B. Datiles, David Alex Jacobsohn, Theo Heller, Carrie Lynn Kitko, Sandra A. Mitchell, Paul J. Martin, Howard M. Shulman, Roy S. Wu, Corey S. Cutler, Georgia B. Vogelsang, Stephanie Joi Lee, Steven Zivko Pavletic, Mary E.D. Flowers

Transplantation and Cellular Therapy · 2014 · 5,547 citationsOpen access

No retraction on record in OpenAlex.Check Crossref now

Cite this paper

Jagasia, M., Greinix, H., Arora, M., Williams, K. M., Wolff, D., Cowen, E. W., Palmer, J. M., Weisdorf, D. J., Treister, N. S., Cheng, G., Kerr, H. M., Stratton, P., Duarte, R. F., McDonald, G. B., Inamoto, Y., Vigorito, A. C., Arai, S., Datiles, M. B., Jacobsohn, D. A., … Flowers, M. E. (2014). National institutes of health consensus development project on criteria for clinical trials in chronic Graft-versus-Host disease: I. The 2014 diagnosis and staging working group report. Transplantation and Cellular Therapy, 21(3), 389–401.e1. https://doi.org/10.1016/j.bbmt.2014.12.001

In text: (Jagasia et al., 2014)

Ask a question about this research

One question, free, no account. Anchorcite finds the papers, checks each against Crossref and links every sentence of the answer to the passage it comes from.

Abstract

The 2005 National Institutes of Health (NIH) Consensus Conference proposed new criteria for diagnosing and scoring the severity of chronic graft-versus-host disease (GVHD). The 2014 NIH consensus maintains the framework of the prior consensus with further refinement based on new evidence. Revisions have been made to address areas of controversy or confusion, such as the overlap chronic GVHD subcategory and the distinction between active disease and past tissue damage. Diagnostic criteria for involvement of mouth, eyes, genitalia, and lungs have been revised. Categories of chronic GVHD should be defined in ways that indicate prognosis, guide treatment, and define eligibility for clinical trials. Revisions have been made to focus attention on the causes of organ-specific abnormalities. Attribution of organ-specific abnormalities to chronic GVHD has been addressed. This paradigm shift provides greater specificity and more accurately measures the global burden of disease attributed to GVHD, and it will facilitate biomarker association studies.

  1. International Scoring System for Evaluating Prognosis in Myelodysplastic Syndromes1997
  2. Effectiveness of Donor Natural Killer Cell Alloreactivity in Mismatched Hematopoietic Transplants2002

Metadata from OpenAlex (CC0). Citations are generated from the published record.